{"id":510698,"date":"2021-07-08T06:33:07","date_gmt":"2021-07-08T10:33:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/"},"modified":"2021-07-08T06:33:07","modified_gmt":"2021-07-08T10:33:07","slug":"sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/","title":{"rendered":"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit on July 13<sup>th<\/sup> at 2:25pm ET.\n<\/p>\n<p>\nA live webcast of the presentation can be accessed on the investor page of Sage&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestor.sagerx.com&amp;esheet=52456430&amp;newsitemid=20210708005048&amp;lan=en-US&amp;anchor=investor.sagerx.com&amp;index=1&amp;md5=7d3ceeaf46d1bbe5bfd747e068144dbf\">investor.sagerx.com<\/a>. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.\n<\/p>\n<p><b>About Sage Therapeutics<br \/>\n<br \/><\/b>Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sagerx.com&amp;esheet=52456430&amp;newsitemid=20210708005048&amp;lan=en-US&amp;anchor=www.sagerx.com&amp;index=2&amp;md5=cd5abe32093606496bbd169b842e0de8\">www.sagerx.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210708005048\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210708005048\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Jeff Boyle<br \/>\n<br \/>617-949-4256<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Jeff.Boyle@sagerx.com\">Jeff.Boyle@sagerx.com<\/a><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Maureen L. Suda<br \/>\n<br \/>617-949-4289<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:maureen.suda@sagerx.com\">maureen.suda@sagerx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Mental Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210708005048\/en\/736779\/3\/Sage_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit on July 13th at 2:25pm ET. A live webcast of the presentation can be accessed on the investor page of Sage&#8217;s website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510698","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit on July 13th at 2:25pm ET. A live webcast of the presentation can be accessed on the investor page of Sage&#8217;s website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics is &hellip; Continue reading &quot;Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-08T10:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit\",\"datePublished\":\"2021-07-08T10:33:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/\"},\"wordCount\":266,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/\",\"name\":\"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-08T10:33:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/","og_locale":"en_US","og_type":"article","og_title":"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit - Market Newsdesk","og_description":"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit on July 13th at 2:25pm ET. A live webcast of the presentation can be accessed on the investor page of Sage&#8217;s website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics is &hellip; Continue reading \"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-08T10:33:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit","datePublished":"2021-07-08T10:33:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/"},"wordCount":266,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/","name":"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-08T10:33:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005048r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-to-participate-in-cowens-psychedelics-novel-mechanisms-in-neuropsychiatry-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sage Therapeutics to Participate in Cowen\u2019s Psychedelics &amp; Novel Mechanisms in Neuropsychiatry Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510698"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}